IGFBP-2 Antibody (92326) [Unconjugated]

(A) Elisa determination of IGFBP-2 and -5 concentrations in conditioned medium (CM) from wt and TamR MCF-7 cell lines. Data represent mean ± SD (n = 3). Experiments were repeated on three separate occasions. *p < 0.001, **p < 0.0001 (Student's unpaired t-test). (B) Western blot (upper two panels) and Ligand blot (lower panel) identifies IGFBP-2 (upper arrow Ligand blot) and IGFBP-5 (lower panel Ligand blot) in CM from wt and TamR MCF-7 cells. (C) Densitometric analysis of Western blots for IGFBP-2 (upper graph) and IGFBP-5 (lower graph) band intensity. Triplicate lanes per blot were analysed for both wt and TamR conditioned media using Image Lab software. Data are presented as mean +/− SD (n = 3) of Arbitrary Unit (AU) intensity. This experiment was repeated 3 times with similar results in each instance. *p < 0.005 TamR v MCF-7 Students t-test. GraphPad Prism 5.0. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27050076), licensed under a CC-BY license. Not internally tested by R&D Systems.

674-B2) was serially diluted and captured by Mouse Anti-Human IGFBP‑2 Monoclonal Antibody (Catalog # MAB6741) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human IGFBP‑2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF674) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" > 674-B2) was serially diluted and captured by Mouse Anti-Human IGFBP‑2 Monoclonal Antibody (Catalog # MAB6741) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human IGFBP‑2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF674) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" title="Recombinant Human IGFBP‑2 (Catalog # 674-B2) was serially diluted and captured by Mouse Anti-Human IGFBP‑2 Monoclonal Antibody (Catalog # MAB6741) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human IGFBP‑2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF674) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" />

Recombinant Human IGFBP‑2 (Catalog # <a class=

• Applications: WB, ELISA(Cap)
• Clone: 92326
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

IGFBP-2 Antibody (92326) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human IGFBP‑2
  Glu40-Gln328
  Accession # CAA34373
• Specificity: Detects human IGFBP-2 in direct ELISAs and Western blots. In Western blots, shows less than 1% cross-reactivity with rhIGFBP-1, rhIGFBP‑3, rhIGFBP-4, rhIGFBP-5, and rhIGFBP-6.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: IGFBP2
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Western Blot 1 ug/mL
• Application Notes: ELISA Detection: Human IGFBP-2 Biotinylated Antibody (Catalog number BAF674)
  Standard: Recombinant Human IGFBP-2 (Catalog number 674-B2)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IGFBP-2 Antibody (92326) [Unconjugated]

• BP2
• IBP2
• IBP-2
• IGF-binding protein 2
• IGFBP2
• IGFBP-2
• IGF-BP53
• insulin-like growth factor binding protein 2 (36kD)
• insulin-like growth factor binding protein 2, 36kDa
• insulin-like growth factor-binding protein 2

Background

The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBPs, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. Human IGFBP-2 cDNA encodes a 328 amino acid (aa) residue precursor protein with a putative 39 aa residue signal peptide that is processed to generate the 289 aa residue mature protein. IGFBP-2 contains an integrin receptor recognition sequence (RGD sequence) but lacks potential N-linked glycosylation sites. During development, IGFBP-2 is expressed in a number of tissues. The highest expression level is found in the central nervous system. In adults, high expression levels are also detected in the central nervous system and in a number of reproductive tissues. IGFBP-2 binds preferentially to IGF II, exhibiting a 2-10 fold higher affinity for IGF‑II than for IGF‑I.

1. Jones, J.I. and D.R. Clemmons (1995) Endocrine Rev. 16:3.
2. Kelley, K.M. et al. (1996) Int. J. Biochem. Cell Biol. 28:619.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IGFBP-2 Antibody (MAB6741)(3)

Publications using MAB6741

• Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro Oncotarget, 2016-05-31;7(22):32129-43. 2016-05-31 [PMID: 27050076] (Western Blot, Human)
• Hu H, Kwun J, Aizenstein BD, Knechtle SJ Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation, 2009-06-27;87(12):1814-20. 2009-06-27 [PMID: 19543058] (Antibody Array Development, Human)
• Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T, Chiba T, Asaka M, Ochiai A Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochem. Biophys. Res. Commun., 2005-08-05;333(3):1011-6. 2005-08-05 [PMID: 15964556] (Western Blot, Human)

Bioinformatics

• Gene Symbol: IGFBP2
• Uniprot:
  • CAA34373()